Find Tolcapone manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Annual Reports

NA

199 RELATED EXCIPIENT COMPANIES

327EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 134308-13-7, Tasmar, Ro 40-7592, 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone, Ro-40-7592
Molecular Formula
C14H11NO5
Molecular Weight
273.24  g/mol
InChI Key
MIQPIUSUKVNLNT-UHFFFAOYSA-N
FDA UNII
CIF6334OLY

Tolcapone
A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.
Tolcapone is a Catechol-O-Methyltransferase Inhibitor. The mechanism of action of tolcapone is as a Catechol O-Methyltransferase Inhibitor.
1 2D Structure

Tolcapone

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone
2.1.2 InChI
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
2.1.3 InChI Key
MIQPIUSUKVNLNT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]
2.2 Other Identifiers
2.2.1 UNII
CIF6334OLY
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3,4 Dihydroxy 5' Methyl 5 Nitrobenzophenone

2. 3,4-dihydroxy-5'-methyl-5-nitrobenzophenone

3. Ro 40 7592

4. Ro 40-7592

5. Ro 407592

6. Ro-40-7592

7. Ro407592

8. Som0226

9. Tasmar

2.3.2 Depositor-Supplied Synonyms

1. 134308-13-7

2. Tasmar

3. Ro 40-7592

4. 3,4-dihydroxy-4'-methyl-5-nitrobenzophenone

5. (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone

6. Ro-40-7592

7. (3,4-dihydroxy-5-nitrophenyl)(p-tolyl)methanone

8. (3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone

9. Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-

10. Mfcd00866569

11. Ro-407592

12. Chembl1324

13. Cif6334oly

14. Chebi:63630

15. Ncgc00181767-01

16. 3,4-dihydroxy-5-nitro-4'-methylbenzophenone

17. 4'-methyl-3,4-dihydroxy-5-nitrobenzophenone

18. Dsstox_cid_3685

19. Dsstox_rid_77146

20. Dsstox_gsid_23685

21. Talcapone

22. Unii-cif6334oly

23. Tasmar (tn)

24. Ccris 7904

25. Cas-134308-13-7

26. Tolcapone [usan:usp:inn:ban]

27. Tolcapone- Bio-x

28. Tcw

29. Tolcapone [inn]

30. Tolcapone [jan]

31. Tolcapone [mi]

32. Tolcapone [usan]

33. Tolcapone [vandf]

34. Tolcapone [mart.]

35. Tolcapone [usp-rs]

36. Tolcapone [who-dd]

37. Tolcapone (jan/usp/inn)

38. Schembl33869

39. Tolcapone [ema Epar]

40. Mls006012044

41. Bidd:gt0032

42. Gtpl6646

43. Tolcapone [orange Book]

44. Dtxsid3023685

45. Tolcapone, >=98% (hplc)

46. Methanone,(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)-

47. Tolcapone [usp Monograph]

48. 3s68

49. Hms2089k14

50. Hms3652m17

51. Hms3715d16

52. Hms3872f03

53. Hms3885g18

54. Bcp09156

55. Tox21_112963

56. Tox21_302414

57. 3,4-dihydroxy-4 Inverted Exclamation Mark -methyl-5-nitrobenzophenone

58. Ac-791

59. Bdbm50108877

60. S4021

61. Zinc35342789

62. Akos015902328

63. Tox21_112963_1

64. As-7085

65. Ccg-221217

66. Cs-1173

67. Db00323

68. Ks-1314

69. Ncgc00181767-02

70. Ncgc00181767-03

71. Ncgc00255188-01

72. Bt164481

73. Hy-17406

74. Smr001614567

75. Sy102278

76. Db-013561

77. Ft-0631149

78. Sw219511-1

79. T3856

80. C07949

81. D00786

82. O10068

83. Ab01275441-01

84. Ab01275441_02

85. (3,4-dihydroxy-5-nitro-phenyl)-p-tolyl-methanone

86. 308t137

87. Q413840

88. Sr-05000001444

89. Q-201840

90. Sr-05000001444-1

91. Brd-k10852020-001-01-1

92. 5-[(4-methylphenyl)carbonyl]-3-nitrobenzene-1,2-diol

93. Tolcapone, United States Pharmacopeia (usp) Reference Standard

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 273.24 g/mol
Molecular Formula C14H11NO5
XLogP33.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count2
Exact Mass273.06372245 g/mol
Monoisotopic Mass273.06372245 g/mol
Topological Polar Surface Area103 Ų
Heavy Atom Count20
Formal Charge0
Complexity372
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameTasmar
PubMed HealthTolcapone (By mouth)
Drug ClassesAntiparkinsonian
Drug LabelTASMAR is available as tablets containing 100 mg tolcapone.Tolcapone, an inhibitor of catechol-O-methyltransferase (COMT), is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa therapy. It is a yellow, odorless, non-hy..
Active IngredientTolcapone
Dosage FormTablet
RouteOral
Strength100mg
Market StatusPrescription
CompanyValeant Pharms

2 of 2  
Drug NameTasmar
PubMed HealthTolcapone (By mouth)
Drug ClassesAntiparkinsonian
Drug LabelTASMAR is available as tablets containing 100 mg tolcapone.Tolcapone, an inhibitor of catechol-O-methyltransferase (COMT), is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa therapy. It is a yellow, odorless, non-hy..
Active IngredientTolcapone
Dosage FormTablet
RouteOral
Strength100mg
Market StatusPrescription
CompanyValeant Pharms

4.2 Drug Indication

Used as an adjunct to levodopa/carbidopa therapy for the symptomatic treatment of Parkinson's Disease. This drug is generally reserved for patients with parkinsonian syndrome receiving levodopa/carbidopa who are experiencing symptom fluctuations and are not responding adequately to or are not candidates for other adjunctive therapies.


FDA Label


Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinsons disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors.

Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.

Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Tolcapone is a potent, selective, and reversible inhibitor of catechol-O-methyltransferase (COMT). In humans, COMT is distributed throughout various organs. COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include dopa, catecholamines (dopamine, norepinephrine, epinephrine) and their hydroxylated metabolites. The function of COMT is the elimination of biologically active catechols and some other hydroxylated metabolites. COMT is responsible for the elimination of biologically active catechols and some other hydroxylated metabolites. In the presence of a decarboxylase inhibitor, COMT becomes the major metabolizing enzyme for levodopa catalyzing it to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the brain and periphery. When tolcapone is given in conjunction with levodopa and an aromatic amino acid decarboxylase inhibitor, such as carbidopa, plasma levels of levodopa are more sustained than after administration of levodopa and an aromatic amino acid decarboxylase inhibitor alone. It is believed that these sustained plasma levels of levodopa result in more constant dopaminergic stimulation in the brain, leading to greater effects on the signs and symptoms of Parkinson's disease in patients as well as increased levodopa adverse effects, sometimes requiring a decrease in the dose of levodopa.


5.2 MeSH Pharmacological Classification

Antiparkinson Agents

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)


Catechol O-Methyltransferase Inhibitors

Compounds and drugs that inhibit or block the activity of CATECHOL O-METHYLTRANSFERASE enzymes. Drugs in this class are used in management of central nervous system disorders such as PARKINSON DISEASE. (See all compounds classified as Catechol O-Methyltransferase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
TOLCAPONE
5.3.2 FDA UNII
CIF6334OLY
5.3.3 Pharmacological Classes
Catechol-O-Methyltransferase Inhibitor [EPC]; Catechol O-Methyltransferase Inhibitors [MoA]
5.4 ATC Code

N04BX01


N04BX01

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


N - Nervous system

N04 - Anti-parkinson drugs

N04B - Dopaminergic agents

N04BX - Other dopaminergic agents

N04BX01 - Tolcapone


5.5 Absorption, Distribution and Excretion

Absorption

Rapidly absorbed (absolute bioavailability is about 65%)


Route of Elimination

Tolcapone is almost completely metabolized prior to excretion, with only a very small amount (0.5% of dose) found unchanged in urine. The glucuronide conjugate of tolcapone is mainly excreted in the urine but is also excreted in the bile.


Volume of Distribution

9 L


Clearance

7 L/h


5.6 Metabolism/Metabolites

The main metabolic pathway of tolcapone is glucuronidation


Tolcapone has known human metabolites that include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-[2-hydroxy-4-(4-methylbenzoyl)-6-nitrophenoxy]oxane-2-carboxylic acid.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.7 Biological Half-Life

2-3.5 hours


5.8 Mechanism of Action

The precise mechanism of action of tolcapone is unknown, but it is believed to be related to its ability to inhibit COMT and alter the plasma pharmacokinetics of levodopa, resulting in an increase in plasma levodopa concentrations. The inhibition of COMT also causes a reduction in circulating 3-OMD as a result of decreased peripheral metabolism of levodopa. This may lead to an increase distribution of levodopa into the CNS through the reduction of its competitive substrate, 3-OMD, for transport mechanisms. Sustained levodopa concentrations presumably result in more consistent dopaminergic stimulation, resulting in greater reduction in the manifestations of parkinsonian syndrome.


Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Controlled & Modified Release

read-more
read-more

Direct Compression

read-more
read-more

Granulation

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Solubilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Topical

read-more
read-more

Taste Masking

read-more
read-more

Parenteral

read-more
read-more

Empty Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Vegetarian Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Emulsifying Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Tolcapone Manufacturers

A Tolcapone manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tolcapone, including repackagers and relabelers. The FDA regulates Tolcapone manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tolcapone API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Tolcapone manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Tolcapone Suppliers

A Tolcapone supplier is an individual or a company that provides Tolcapone active pharmaceutical ingredient (API) or Tolcapone finished formulations upon request. The Tolcapone suppliers may include Tolcapone API manufacturers, exporters, distributors and traders.

click here to find a list of Tolcapone suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Tolcapone USDMF

A Tolcapone DMF (Drug Master File) is a document detailing the whole manufacturing process of Tolcapone active pharmaceutical ingredient (API) in detail. Different forms of Tolcapone DMFs exist exist since differing nations have different regulations, such as Tolcapone USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Tolcapone DMF submitted to regulatory agencies in the US is known as a USDMF. Tolcapone USDMF includes data on Tolcapone's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tolcapone USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Tolcapone suppliers with USDMF on PharmaCompass.

Tolcapone WC

A Tolcapone written confirmation (Tolcapone WC) is an official document issued by a regulatory agency to a Tolcapone manufacturer, verifying that the manufacturing facility of a Tolcapone active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tolcapone APIs or Tolcapone finished pharmaceutical products to another nation, regulatory agencies frequently require a Tolcapone WC (written confirmation) as part of the regulatory process.

click here to find a list of Tolcapone suppliers with Written Confirmation (WC) on PharmaCompass.

Tolcapone NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tolcapone as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Tolcapone API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Tolcapone as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Tolcapone and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tolcapone NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Tolcapone suppliers with NDC on PharmaCompass.

Tolcapone GMP

Tolcapone Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Tolcapone GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tolcapone GMP manufacturer or Tolcapone GMP API supplier for your needs.

Tolcapone CoA

A Tolcapone CoA (Certificate of Analysis) is a formal document that attests to Tolcapone's compliance with Tolcapone specifications and serves as a tool for batch-level quality control.

Tolcapone CoA mostly includes findings from lab analyses of a specific batch. For each Tolcapone CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Tolcapone may be tested according to a variety of international standards, such as European Pharmacopoeia (Tolcapone EP), Tolcapone JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tolcapone USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty